因毒性结节性甲状腺肿治疗的患者心血管死亡率和发病率高于Graves病及非毒性甲状腺肿患者
该观察性登记研究纳入1976-2012年斯德哥尔摩因Graves病或毒性结节性甲状腺肿接受放射性碘或手术治疗的12239例患者,与非毒性甲状腺肿3685例及一般人群比较,中位随访18.4年。甲亢患者全因死亡HR 1.27、心血管死亡HR 1.29、心血管发病HR 1.12(均较非毒性甲状腺肿);超额风险主要见于毒性结节性甲状腺肿,且1990年及以后纳入者风险更高。
要点
- ≥45岁接受毒性结节性甲状腺肿治疗者风险一般更高,1990年及以后纳入者风险高于更早纳入者。
核心结论
- 首次大型研究提示甲亢患者长期死亡和心血管疾病风险由甲亢本身所致,而非治疗带来的混杂效应。
- 超额风险大部分限于接受毒性结节性甲状腺肿治疗的患者。
- 尽管近几十年心血管诊疗进步,甲亢仍与心血管发病和死亡增加相关。
研究设计与样本
- 观察性登记研究,期间1976-2012年,中位随访18.4年。
- 研究对象为斯德哥尔摩因Graves病或毒性结节性甲状腺肿接受放射性碘或手术治疗的患者(N=12,239)。
- 对照组为斯德哥尔摩因非毒性甲状腺肿治疗者(N=3,685),并调整年龄、性别、合并症和治疗时间;另与斯德哥尔摩一般人群比较。
主要发现
- 年龄≥45岁接受毒性结节性甲状腺肿治疗者风险一般高于其他人,1990年及以后纳入者风险高于更早纳入者。
- 与一般人群比较亦见全因死亡、心血管死亡和心血管发病增加。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous research has suggested an increased risk of death and cardiovascular disease in patients treated for hyperthyroidism. However, studies on this subject are heterogeneous, often based on old data, or have not considered the impact that treatment for hyperthyroidism might have on cardiovascular risk. It is also unclear whether long-term prognosis differs between Graves' disease and toxic nodular goiter. The aim of this study was to use a very large cohort built on recent data to assess whether improvements in cardiovascular care might have changed the prognosis over time. The study also investigated the impact of different etiologies of hyperthyroidism. METHODS: This was an observational register study for the period 1976-2012, with subjects followed for a median period of 18.4 years. Study patients were Stockholm residents treated for Graves' disease or toxic nodular goiter with either radioactive iodine or surgery (N = 12,239). This group was compared to Stockholm residents treated for nontoxic goiter (N = 3685), with adjustments made for age, sex, comorbidities, and time of treatment. Comparisons were also made to the general population of Stockholm. Outcomes were assessed in terms of all-cause and cardiovascular mortality as well as cardiovascular morbidity. RESULTS: The hazard ratios (HR) for all-cause mortality and for cardiovascular mortality were 1.27 [confidence interval (CI) 1.20-1.35] and 1.29 [CI 1.17-1.42], respectively, for hyperthyroid patients compared to those with nontoxic goiter. For cardiovascular morbidity, the HR was 1.12 [CI 1.06-1.18]. Patients aged ≥45 years who were treated for toxic nodular goiter were generally at greater risk than others, and those included from the year 1990 and onwards were at greater risk than those included earlier. Increased all-cause mortality, as well as cardiovascular mortality and morbidity, were also seen in comparisons with the general population. CONCLUSIONS: This is the first large study to indicate that the long-term risk of death and cardiovascular disease in hyperthyroid subjects is due to the hyperthyroidism itself and not an effect of confounding introduced by its treatment. Much of the excess risk is confined to individuals treated for toxic nodular goiter. Despite advances in cardiovascular care during recent decades, hyperthyroidism is still a diagnosis associated with increased cardiovascular morbidity and mortality.
引用
- Giesecke P, Rosenqvist M, Frykman V, et al. Increased Cardiovascular Mortality and Morbidity in Patients Treated for Toxic Nodular Goiter Compared to Graves' Disease and Nontoxic Goiter. Thyroid. 2017. PMID: 28471268. doi:10.1089/thy.2017.0029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。